Original Article| Volume 23, ISSUE 6, P1545-1553, July 2014

Protective Effect of Telmisartan Against Progressive Oxidative Brain Damage and Synuclein Phosphorylation in Stroke-resistant Spontaneously Hypertensive Rats

      Previously, we reported that reactive oxygen species and signaling molecules of angiotensin II produced lipid peroxides, degenerated proteins, and injured DNA after cerebral ischemia in normotensive Wistar rats. Here, we investigated the long-term effect of the angiotensin II type I receptor blocker telmisartan on oxidative stress and hyperphosphorylated α-synuclein accumulation in stroke-resistant spontaneously hypertensive rats (SHR-SR). At the age of 3 months, SHR-SR were divided into 3 treatment groups: SHR-SR vehicle (SHR/Ve), SHR-SR low-dose telmisartan (.3 mg/kg/day) (SHR/low), and SHR-SR high-dose telmisartan (3 mg/kg/day) (SHR/high). Immunohistologic analyses were conducted in these groups and Wistar rats at the age of 6, 12, and 18 months. The SHR/Ve group demonstrated more progressive increase in advanced glycation end product (AGE)-, 4-hydroxy-2-nonenal (4-HNE)-, and phosphorylated α-synuclein (pSyn)-positive cells in the cerebral cortex and hippocampus compared with the Wistar group at 18 months. These expressions were reduced in the SHR/low group even without lowering blood pressure (BP), and expressions were dramatically suppressed in the SHR/high group with lowering of BP. These data suggest that persistent hypertension in SHR-SR strongly potentiate the markers of oxidative damage (AGEs and 4-HNE) and abnormal accumulation of pSyn, which were greatly suppressed by telmisartan in a dose-dependent manner without and with lowering of BP.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Stroke and Cerebrovascular Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Zhang W.
        • Sato K.
        • Hayashi T.
        • et al.
        Extension of ischemic therapeutic time window by a free radical scavenger, Edaravone, reperfused with tPA in rat brain.
        Neurol Res. 2004; 26: 342-348
        • Nagotani S.
        • Hayashi T.
        • Sato K.
        • et al.
        Reduction of cerebral infarction in stroke-prone spontaneously hypertensive rats by statins associated with amelioration of oxidative stress.
        Stroke. 2005; 36: 670-672
        • Dahlof B.
        • Devereux R.B.
        • Kjeldsen S.E.
        • et al.
        Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
        Lancet. 2002; 359: 995-1003
        • Rueckschloss U.
        • Quinn M.T.
        • Holtz J.
        • et al.
        Dose-dependent regulation of NAD(P)H oxidase expression by angiotensin II in human endothelial cells: protective effect of angiotensin II type 1 receptor blockade in patients with coronary artery disease.
        Arterioscler Thromb Vasc Biol. 2002; 22: 1845-1851
        • Tsuda M.
        • Iwai M.
        • Li J.M.
        • et al.
        Inhibitory effects of AT1 receptor blocker, olmesartan, and estrogen on atherosclerosis via anti-oxidative stress.
        Hypertension. 2005; 45: 545-551
        • Schrader J.
        • Luders S.
        • Kulschewski A.
        • et al.
        The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors.
        Stroke. 2003; 34: 1699-1703
        • Schrader J.
        • Luders S.
        • Kulschewski A.
        • et al.
        Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES).
        Stroke. 2005; 36: 1218-1226
        • Maillard M.P.
        • Perregaux C.
        • Centeno C.
        • et al.
        In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist.
        J Pharmacol Exp Ther. 2002; 302: 1089-1095
        • Gohlke P.
        • Weiss S.
        • Jansen A.
        • et al.
        AT1 receptor antagonist telmisartan administered peripherally inhibits central responses to angiotensin II in conscious rats.
        J Pharmacol Exp Ther. 2001; 298: 62-70
        • Mogi M.
        • Li J.M.
        • Tsukuda K.
        • et al.
        Telmisartan prevented cognitive decline partly due to PPAR-gamma activation.
        Biochem Biophys Res Commun. 2008; 375: 446-449
        • Wultz B.
        • Sagvolden T.
        • Moser E.I.
        • et al.
        The spontaneously hypertensive rat as an animal model of attention-deficit hyperactivity disorder: effects of methylphenidate on exploratory behavior.
        Behav Neural Biol. 1990; 53: 88-102
        • Sabbatini M.
        • Catalani A.
        • Consoli C.
        • et al.
        The hippocampus in spontaneously hypertensive rats: an animal model of vascular dementia?.
        Mech Ageing Dev. 2002; 123: 547-559
        • Sanz-Rosa D.
        • Oubina M.P.
        • Cediel E.
        • et al.
        Eplerenone reduces oxidative stress and enhances eNOS in SHR: vascular functional and structural consequences.
        Antioxid Redox Signal. 2005; 7: 1294-1301
        • Kumai Y.
        • Ooboshi H.
        • Ago T.
        • et al.
        Protective effects of angiotensin II type 1 receptor blocker on cerebral circulation independent of blood pressure.
        Exp Neurol. 2008; 210: 441-448
        • Suematsu M.
        • Suzuki H.
        • Delano F.A.
        • et al.
        The inflammatory aspect of the microcirculation in hypertension: oxidative stress, leukocytes/endothelial interaction, apoptosis.
        Microcirculation. 2002; 9: 259-276
        • Ikeda K.
        • Kitamura A.
        • Machida H.
        • et al.
        Effect of Undaria pinnatifida (Wakame) on the development of cerebrovascular diseases in stroke-prone spontaneously hypertensive rats.
        Clin Exp Pharmacol Physiol. 2003; 30: 44-48
        • Chau K.Y.
        • Ching H.L.
        • Schapira A.H.
        • et al.
        Relationship between alpha synuclein phosphorylation, proteasomal inhibition and cell death: relevance to Parkinson's disease pathogenesis.
        J Neurochem. 2009; 110: 1005-1013
        • Wienen W.
        • Schierok H.J.
        Effects of telmisartan, hydrochlorothiazide and their combination on blood pressure and renal excretory parameters in spontaneously hypertensive rats.
        J Renin Angiotensin Aldosterone Syst. 2001; 2: 123-128
        • Burlacu A.
        • Jinga V.
        • Gafencu A.V.
        • et al.
        Severity of oxidative stress generates different mechanisms of endothelial cell death.
        Cell Tissue Res. 2001; 306: 409-416
        • Didion S.P.
        • Faraci F.M.
        Angiotensin II produces superoxide-mediated impairment of endothelial function in cerebral arterioles.
        Stroke. 2003; 34: 2038-2042
        • Hanna I.R.
        • Taniyama Y.
        • Szocs K.
        • et al.
        NAD(P)H oxidase-derived reactive oxygen species as mediators of angiotensin II signaling.
        Antioxid Redox Signal. 2002; 4: 899-914
        • Rajagopalan S.
        • Kurz S.
        • Munzel T.
        • et al.
        Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone.
        J Clin Invest. 1996; 97: 1916-1923
        • Giasson B.I.
        • Duda J.E.
        • Murray I.V.
        • et al.
        Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions.
        Science. 2000; 290: 985-989
        • Fujiwara H.
        • Hasegawa M.
        • Dohmae N.
        • et al.
        alpha-Synuclein is phosphorylated in synucleinopathy lesions.
        Nat Cell Biol. 2002; 4: 160-164
        • Sugeno N.
        • Takeda A.
        • Hasegawa T.
        • et al.
        Serine 129 phosphorylation of alpha-synuclein induces unfolded protein response-mediated cell death.
        J Biol Chem. 2008; 283: 23179-23188
        • Benson S.C.
        • Pershadsingh H.A.
        • Ho C.I.
        • et al.
        Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity.
        Hypertension. 2004; 43: 993-1002
        • Modrick M.L.
        • Kinzenbaw D.A.
        • Chu Y.
        • et al.
        Peroxisome proliferator-activated receptor-gamma protects against vascular aging.
        Am J Physiol Regul Integr Comp Physiol. 2012; 302: R1184-R1190
        • Kurihara T.
        • Ozawa Y.
        • Shinoda K.
        • et al.
        Neuroprotective effects of angiotensin II type 1 receptor (AT1R) blocker, telmisartan, via modulating AT1R and AT2R signaling in retinal inflammation.
        Invest Ophthalmol Vis Sci. 2006; 47: 5545-5552
        • Ola M.S.
        • Ahmed M.M.
        • Abuohashish H.M.
        • et al.
        Telmisartan ameliorates neurotrophic support and oxidative stress in the retina of streptozotocin-induced diabetic rats.
        Neurochem Res. 2013; 38: 1572-1579
        • Min L.J.
        • Mogi M.
        • Shudou M.
        • et al.
        Peroxisome proliferator-activated receptor-gamma activation with angiotensin II type 1 receptor blockade is pivotal for the prevention of blood-brain barrier impairment and cognitive decline in type 2 diabetic mice.
        Hypertension. 2012; 59: 1079-1088